California Has Three Months to Prove Its Meth Treatment Program Deserves to Survive

Show up, give a urine sample, and if it’s negative for stimulants, walk out with a gift card. That’s the entire mechanism of contingency management (CM) — paying people small, escalating rewards for verified drug-negative tests — and it’s the reason a participant in one California program told Filter that a “non-judgmental group of people” let them show up “no matter what shape I was in.” It sounds too simple to count as medicine. The American Society of Addiction Medicine treats it as the standard of care anyway, because for stimulant use disorder — problem use of cocaine or methamphetamine — there is no other standard. Opioid use disorder has buprenorphine, methadone, naltrexone. Alcohol use disorder has naltrexone, acamprosate, disulfiram. Stimulant use disorder has zero FDA-approved medications. None.

A treatment with no medication to fall back on is being asked to prove its worth on a deadline no medication-based treatment has ever faced.

California got there first. In December 2021, CMS approved the state’s Recovery Incentives Program as the first Medicaid benefit of its kind, using a Section 1115 waiver — the mechanism states use to test coverage Medicaid doesn’t normally pay for. Washington followed in June 2023. Three more states, Delaware, Hawaii, and Montana, have since won approval too, per KFF, bringing the count to five, with Michigan and Rhode Island still pending. That’s real momentum — Rize covered the broader trend here — but it still leaves 45 states’ Medicaid programs offering people with stimulant use disorder nothing that resembles the evidence-based option.

And California, the state carrying the biggest bet, is the one on the clock. By the end of 2026, its Medicaid director has to demonstrate that Recovery Incentives is worth the continued federal match — this is a $58.5 million pilot, $26.7 million of it federal money, built around gift cards capped at roughly $599 per participant over six months. Nobody asked that question of buprenorphine when it rolled into Medicaid formularies. Nobody’s demanding methadone clinics justify their existence county by county on a countdown. But CM — the thing ASAM says actually works for meth and cocaine — still has to re-earn its funding like a pilot program, five years after CMS called it real medicine.

If California can’t make the case, the map doesn’t grow to include the two states still waiting. It shrinks back toward zero. The upside is that the state has the data to make it: retention gains and fewer emergency visits among participants, per Health Law & Policy. Whether that’s convincing enough for whoever’s counting the federal dollars in January is the actual story here — not another “CM is promising” recap, but the specific test of whether evidence, on its own, is enough to keep a $12 gift card flowing to someone who stayed clean one more week.